Evidence map›Paper›PMID 40106222›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2025

Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study.

Manel Pladevall-Vila, Ryan Ziemiecki, Catherine B Johannes, Anam M Khan, Daniel Mines, Natalie Ebert, Csaba P Kovesdy, Reimar W Thomsen, Brenda N Baak, Aníbal García-Sempere and 23 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05526157. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05526157 completed

FINErenone druG Utilization Study and Assessment of Temporal Changes Following Availability of Different Treatment Options in Patients With Chronic Kidney Disease and Type 2 Diabetes

Ran2022Enrolled50,000Registered outcomes5Posted comparisons0ConditionsChronic Kidney Disease, Type 2 Diabetes MellitusArmsFinerenone (Kerendia, BAY 948862), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Non-steroidal mineral corticoid receptor antagonists (nsMRA), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Steroidal mineral corticoid receptor antagonists (sMRA)
Open the trial in the graph
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Manel Pladevall-VilaRTI Health Solutions, Barcelona, Spain.
Ryan ZiemieckiRTI Health Solutions, Research Triangle Park, NC, USA.
Catherine B JohannesRTI Health Solutions, Waltham, MA, USA.
Anam M KhanRTI Health Solutions, Waltham, MA, USA.
Daniel MinesThe Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, MI, USA.
Natalie EbertInstitute of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Csaba P KovesdyDivision of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Reimar W ThomsenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Brenda N BaakPHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
Aníbal García-SempereHealth Services Research and Pharmacoepidemiology Unit, Fisabio, Spain.
Hiroshi KanegaeGenki Plaza Medical Centre for Health Care, Tokyo, Japan.
Craig I ColemanUniversity of Connecticut School of Pharmacy, Storrs, CT, USA.
Michael WalshDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Ina Trolle AndersenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Clara Rodríguez BernalHealth Services Research and Pharmacoepidemiology Unit, Fisabio, Spain.
Celia Robles CabaniñasHealth Services Research and Pharmacoepidemiology Unit, Fisabio, Spain.
Christian Fynbo ChristiansenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Alfredo E FarjatBayer AG, Leverkusen, Germany.
Alain GayNational Kidney Foundation Advocacy, Richmond, VA, USA.
Patrick GeeNational Kidney Foundation Advocacy, Richmond, VA, USA.
Ron M C HeringsPHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
Isabel HurtadoHealth Services Research and Pharmacoepidemiology Unit, Fisabio, Spain.
Naoki KashiharaDepartment of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan.
Frederik Pagh Bredahl KristensenDepartment of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Fangfang LiuBayer AG, Leverkusen, Germany.
Suguru OkamiBayer AG, Leverkusen, Germany.
Jetty A OverbeekPHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
Fernie J A Penning-van BeestPHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
Satoshi YamashitaBayer AG, Leverkusen, Germany.
Yuichiro YanoDepartment of General Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan.
J Bradley LaytonRTI Health Solutions, Research Triangle Park, NC, USA.
David VizcayaBayer AG, Leverkusen, Germany.
Nikolaus G OberprielerBayer AG, Leverkusen, Germany. niki.oberprieler@bayer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNovel therapies are emerging for the prevention of chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D). Within the FOUNTAIN platform (NCT05526157; EUPAS48148), this real-world study aimed to characterize cohorts of adults with CKD and T2D starting therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in Europe, Japan, and the United States (US) during 2012-2021.

methodsThis multinational, multicohort study was conducted in five data sources: the Danish National Health Registers (DNHR) (Denmark), PHARMO Data Network (PHARMO) (The Netherlands), Valencia Health System Integrated Database (VID) (Spain), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) (Japan), and Optum's de-identified Clinformatics® Data Mart Database (CDM) (US). Eligible patients had T2D (defined by data source-specific algorithms) and CKD (based on diagnosis codes, estimated glomerular filtration rate values, and/or urine albumin-to-creatinine ratio) and initiated an GLP-1 RA during 2012-2021. Baseline demographic, lifestyle, and clinical characteristics were analyzed, and treatment patterns were described.

resultsStudy cohorts included 18,929 GLP-1 RA initiators in DNHR; 476 in PHARMO; 11,798 in VID; 329 in J-CKD-DB-Ex; and 70,158 in CDM. Across cohorts, mean age ranged from 66.1 years in J-CKD-DB-Ex to 67.9 years in CDM, and between 46.6% (PHARMO) and 59.6% (J-CKD-DB-Ex) of patients were men. There was a steady increase in GLP-1 RA initiators from 2012 (when 1.6-4.8% of GLP-1 RA initiators started therapy) to 2019 (when 19.8-31.5% started therapy). The median duration of initial treatment with a GLP-1 RA ranged from 2.3 months (PHARMO) to 12.4 months (VID). At 1-year follow-up, between 52% (CDM) and 78% (DNHR) of patients were receiving treatment. Findings suggested that GLP-1 RA use was independent of CKD severity.

conclusionsDuring 2012-2021, GLP-1 RA use steadily increased across multinational cohorts of patients with T2D and CKD, and persistence with treatment was high. GLP-1 use was independent of CKD severity.

Indexed as

ChronicChronic kidney diseaseDiabetes mellitusDrug utilizationFOUNTAIN platformGlucagon-like peptide-1 receptor agonistsRenal insufficiencyType 2

Identifiers

PMID40106222
PMCPMC12006594

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.